All Stories

  1. CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy
  2. A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma
  3. Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review
  4. Cell-Based Tracers as Trojan Horses for Image-Guided Surgery
  5. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging
  6. Vitamin D in Head and Neck Cancer: a Systematic Review
  7. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma
  8. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment
  9. Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study
  10. Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer
  11. Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
  12. Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases
  13. EGFR and αvβ6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region
  14. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy
  15. Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers
  16. Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging
  17. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer
  18. A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer
  19. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer
  20. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation
  21. Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma
  22. Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis
  23. Targeting integrin alpha5 receptor in pancreatic stellate cells to diminish tumor-promoting effects in pancreatic cancer
  24. Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
  25. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma
  26. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma
  27. Morphological and phenotypical features of ovarian metastases in breast cancer patients
  28. uPAR directed-imaging of head-and-neck cancer
  29. Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer
  30. Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types
  31. Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery
  32. Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue
  33. In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer
  34. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
  35. Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery
  36. EpCAM as multi-tumour target for near-infrared fluorescence guided surgery
  37. Selecting tumor targets for dummies
  38. Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery
  39. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue
  40. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer
  41. Stromal Targets for Fluorescent-Guided Oncologic Surgery
  42. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors
  43. uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery
  44. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer
  45. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study
  46. Bone healing and Mannose-Binding Lectin
  47. Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal Cancer
  48. Circulating bone morphogenetic protein levels and delayed fracture healing
  49. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts
  50. Injury pattern, injury severity, and mortality in 33,495 hospital-admitted victims of motorized two-wheeled vehicle crashes in The Netherlands
  51. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients
  52. Reply to the letter to the editor: Could the use of bone morphogenetic proteins in fracture healing do more harm than good to our patients?
  53. Displaced midshaft fractures of the clavicle: non-operative treatment versus plate fixation (Sleutel-TRIAL). A multicentre randomised controlled trial
  54. Use and efficacy of bone morphogenetic proteins in fracture healing
  55. Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
  56. Implant removal associated complications in children with limb fractures due to trauma
  57. Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer
  58. Matrix Metalloproteinase-14 (MT1-MMP)-Mediated Endoglin Shedding Inhibits Tumor Angiogenesis
  59. 5-Aminosalicylic acid inhibits TGF-β1 signalling in colorectal cancer cells
  60. Clinical significance of stromal apoptosis in colorectal cancer
  61. Expression of endoglin (CD105) in cervical cancer
  62. Active TGF-β1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence
  63. Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohnʼs disease
  64. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis
  65. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not
  66. Efficient degradation-aided selection of protease inhibitors by phage display
  67. Endothelium specific matrilysin (MMP-7) expression in human cancers
  68. Eradication of Helicobacter pylori Infection Favourably Affects Altered Gastric Mucosal MMP-9 Levels
  69. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer
  70. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype
  71. Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients
  72. Determination of matrilysin activity in gastrointestinal neoplasia
  73. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer
  74. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces β-glucan-dependent CR3-dependent cellular cytotoxicity
  75. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer
  76. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma
  77. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases
  78. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation
  79. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice
  80. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma
  81. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage
  82. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor
  83. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices
  84. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo
  85. MMP-9 Activity in Urine from Patients with Various Tumors, as Measured by a Novel MMP Activity Assay Using Modified Urokinase as a Substrate
  86. Superoxide dismutases in relation to the overall survival of colorectal cancer patients
  87. High performance density gradient electrophoresis of subcellular organelles, protein complexes and proteins
  88. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer
  89. Gastric mucosal plasminogen activators inHelicobacter pylori infection
  90. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
  91. The effect of treatment of Helicobacter pylori infection on gastric mucosal plasminogen activators
  92. Prognostic value of the plasminogen activation system in patients with gastric carcinoma
  93. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer
  94. Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis
  95. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis
  96. Tetranectin expression in human colonic neoplasia
  97. Urokinase receptor and colorectal cancer survival
  98. Glutathione S-transferases in liver metastases of colorectal cancer. A comparison with normal liver and primary carcinomas
  99. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
  100. Association of aneuploidy in index adenomas with metachronous colorectal adenoma development and a comparison
  101. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia
  102. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum
  103. Matrix Metalloproteinases in Chronic Liver Disease and Liver Transplantation